Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 10 October 2017 | By Zachary Brennan
Boehringer Ingelheim has questions on how new US Food and Drug Administration (FDA) draft guidance on optional child-resistant packaging (CRP) statements will benefit health care professionals and consumers.
The draft guidance, released 2 August, offers help for drugmakers looking to use the statements and ensure they are clear, useful, informative and, to the extent possible, consistent in content and format.
Boehringer, however, questions "whether this new draft guidance on optional statements for CRP, however well intentioned, could inadvertently introduce confusion to consumers if some drug products have such CRP statements and others do not."
The drugmaker also notes that many prescription drugs, particularly solid oral drug products, are repackaged by pharmacists for dispensing, so CRP labeling statements in the manufacturer's labeling may not reach the consumer.
"Thus, it is not clear how manufacturer's labeling of a child-resistant package is expected to benefit healthcare professionals and consumers," Boehrineger said, also noting that if statements about CRP packaging are more commonly applied in labeling, this could dilute the impact of another important safety message to consumers that is required and that says a package is not child resistant.
The American Academy of Family Physicians also offered FDA six recommendations to:
The American Academy of Pediatrics, meanwhile, noted that while the guidance "is voluntary, we urge FDA to use all available options to ensure compliance with these recommendations."
Comments
Tags: child-resistant packaging, Boehringer Ingelheim, FDA draft guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.